Synergistic Inhibition of PI3K and HSP90 Enhanced Antitumorigenic Efficacy in Adrenocortical Carcinoma

Adrenocortical cancer (ACC) is a rare and aggressive malignancy with poor survival due to a lack of effective treatments; therefore, it is important to identify therapies that can be readily studied in clinical trials. Quantitative high-throughput drug combination screening identified potent synergy between phosphatidylinositol-3-kinase (PI3K) inhibition and heat shock protein 90 (HSP90) inhibition. This GEO submission contains the 18 bulk RNA-seq samples from NCI-H295R ACC cells that were used in the publication to evaluate transcriptional responses to PI3K and HSP90 inhibitors alone and in combination. The submitted samples include untreated controls and cells treated with STA9090, PIK75, BGT226, STA9090+PIK75, or STA9090+BGT226, with three biological replicates per condition. These RNA-seq data supported the comparison of molecular responses induced by PI3K/HSP90 inhibitor combinations in ACC cells, including distinct responses associated with PIK75+STA9090 and BGT226+STA9090 treatment.